Pfizer on Wednesday said its COVID-19 vaccine, jointly developed with BioNTech, is 95% effective according to a final analysis of clinical trial data. 

The shot protects all ages and ethnicities. So far, there have been no significant safety issues. Pfizer will apply for emergency use authorization in the US within days.

The headline readout is better than the 90% efficacy Pfizer reported last week, in an initial assessment of the data. It comes just two days after Moderna ...

Subscription required for Premium stories

In order to view the entire article please login with a valid subscription below or register an account and subscribe to Premium
Premium subscriber
New Premium subscriber REGISTER

Comment on this article

You must be logged in to post a comment.